All In Biotech

Drug Trial Radar · NCT03832998

Efficacy and Safety of Erenumab in Pediatric Subjects With Chronic Migraine

A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Efficacy and Safety of Erenumab in Children (6 to < 12 Years) and Adolescents (12 to < 18 Years) With Chronic Migraine (OASIS PEDIATRIC [CM])

Last checked: Nov 20, 2026Latest source record: Oct 28, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 284 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

284

Actual

Start

Sep 5, 2019

Primary completion

Jan 8, 2025

Study completion Jan 7, 2026

Sponsor

Lead sponsor
AmgenAmgen (AMGN)
Sponsor type
Industry
Collaborators
Novartis
First posted
Feb 6, 2019

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 6 years, up to 17 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study will evaluate the efficacy and safety of erenumab in migraine prevention in children (6 to \<12 years) and adolescents (12 to \<18 years) with chronic migraine. The study hypothesis is that in pediatric participants with chronic migraine, the combined erenumab dose group has a greater reduction from baseline to week 9 through week 12 (month 3) in monthly migraine days (MMDs) when compared with placebo in the double-blind treatment phase (DBTP).

Conditions

  • Migraine

Interventions

  • Erenumab Dose 1Drug

    Participants in the low body-weight group at day 1 and who are randomized to Dose Level 1 will receive this dose.

  • Erenumab Dose 2Drug

    Participants in the low body-weight group at day 1 who are randomized to Dose Level 2 and participants in the high body-weight group at day 1 who are randomized to Dose Level 1 will receive this dose.

  • Erenumab Dose 3Drug

    Participants in the high body-weight group at day 1 who are randomized to Dose Level 2 will receive this dose.

  • PlaceboOther

    Placebo matching dose for erenumab dose 1, 2 and 3.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change From Baseline in MMD to Week 9 Through Week 12 (Month 3) of the DBTPTime frame: Baseline to Week 12

Locations

101 sites in 13 countries. Site status is shown where the registry gives one.

  • Paradigm Clinical Research Center Inc

    San Diego, California

  • Childrens Hospital Colorado

    Aurora, Colorado

  • Colorado Springs Neurological Associates

    Colorado Springs, Colorado

  • New England Institute for Clinical Research

    Stamford, Connecticut

  • Childrens National Health System

    Washington D.C., District of Columbia

  • TrueBlue Clinical Research

    Brandon, Florida

  • Northwest Florida Clinical Research Group Limited Liability Company

    Gulf Breeze, Florida

  • Nicklaus Childrens Hospital

    Miami, Florida

  • Pediatric Epilepsy and Neurology Specialists

    Tampa, Florida

  • Premiere Research Institute

    West Palm Beach, Florida

  • Rare Disease Research Center Pediatrics

    Atlanta, Georgia

  • CenExel iResearch, LLC

    Savannah, Georgia

  • Northwestern University

    Chicago, Illinois

  • Chicago Headache Center and Research Institute

    Chicago, Illinois

  • Josephson Wallack Munshower Neurology

    Indianapolis, Indiana

  • University of Maryland, Baltimore

    Baltimore, Maryland

  • New England Regional Headache Center Inc

    Worcester, Massachusetts

  • Michigan Head Pain and Neurological Institute

    Ann Arbor, Michigan

  • Clinical Research Institute Inc

    Plymouth, Minnesota

  • Childrens Mercy Hospital and Clinics

    Kansas City, Missouri

  • Mercy Research

    St Louis, Missouri

  • Meridian Clinical Research LLC

    Hastings, Nebraska

  • Dent Neurosciences Research Center

    Amherst, New York

  • Modern Migraine MD

    New York, New York

  • Columbia University Irving Medical Center

    New York, New York

  • Cincinnati Childrens Hospital Medical Center

    Cincinnati, Ohio

  • Cleveland Clinic Foundation

    Cleveland, Ohio

  • Nationwide Childrens Hospital

    Columbus, Ohio

  • Oregon Health and Science University

    Portland, Oregon

  • Childrens Hospital of Philadelphia

    Philadelphia, Pennsylvania

  • Preferred Primary Care Physicians, Inc

    Pittsburgh, Pennsylvania

  • Palmetto Gastroenterology Clinical Research, LLC

    Summerville, South Carolina

  • Child Neurology Consultants of Austin

    Austin, Texas

  • Helios Clinical Research Inc

    Burleson, Texas

  • Stryde Consulting LLC

    Frisco, Texas

  • Childrens Specialty Group

    Norfolk, Virginia

  • Vaught Neurological Services

    Crab Orchard, West Virginia

  • Marshfield Clinic

    Marshfield, Wisconsin

  • Universitair Ziekenhuis Brussel

    Brussels, Belgium

  • Algemeen Ziekenhuis Sint-Maarten

    Mechelen, Belgium

Showing 40 of 101 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.